July 13, 2014 5:03 PM ET


Company Overview of iCeutica Inc.

Company Overview

iCeutica Inc. develops a pipeline of reformulated and improved products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. The company was founded in 2003 and is based in Philadelphia, Pennsylvania with a facility in Perth, Australia. As of April 28, 2011, iCeutica Inc. operates as a subsidiary of Iroko Pharmaceuticals, LLC.

1 Crescent Drive

Navy Yard Corporate Center

Suite 400

Philadelphia, PA 19112

United States

Founded in 2003





Key Executives for iCeutica Inc.

Chief Executive Officer
Age: 41
Vice President of Clinical Development and Regulatory Affairs
Vice President of Research and Development
Chief Business Officer
Age: 58
Chief Scientific Officer
Compensation as of Fiscal Year 2014.

iCeutica Inc. Key Developments

iCeutica Inc. Names Jyrki Mattila as Chief Business Officer

iCeutica Inc. hired Jyrki Mattila as chief business officer. Mattila served as president and CEO of LZ Therapeutics Inc.

iCeutica Inc. Appoints Jyrki Mattila as Chief Business Officer

iCeutica Inc. announced that Jyrki Mattila, M.D., Ph.D., has joined the company as Chief Business Officer. Dr. Mattila brings over twenty-five years of business development and management experience to iCeutica and has negotiated and closed over fifty business agreements, including in- and out- licensing, co-marketing, collaboration and product acquisition arrangements. Prior to joining iCeutica, Dr. Mattila served as President and CEO of LZ Therapeutics Inc.

iCeutica Announces Positive Top-Line Phase 1 Results of ICE 1201

iCeutica announced positive top-line results from its Phase 1 trial of ICE 1201, a submicron version of metaxalone, a muscle relaxant indicated for the treatment of acute, painful musculoskeletal conditions. Trial results demonstrated improved oral bioavailability, decreased pharmacokinetic variability, more rapid absorption and decreased food effect, when compared to the currently marketed metaxalone product, SKELAXIN. Both ICE 1201 and SKELAXIN were well tolerated, with only mild adverse. The Phase 1 trial enrolled 20 healthy volunteers. Utilizing a four-way crossover design, the study evaluated patients’ response to a 300mg dose of ICE 1201, a 600mg dose of ICE 1201, an 800mg dose of SKELAXIN®, and a 600mg dose of ICE 1201 following a fatty meal.

Similar Private Companies By Industry

Company Name Region
Oncobiologics, Inc. United States
BioProtection Systems Corporation United States
AbVitro, Inc. United States
BioQuanta Corp. United States
Labnetics United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact iCeutica Inc., please visit www.iceutica.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.